Genmab A/S logo
Genmab A/S GMAB
$ 25.59 -0.35%

Quarterly report 2022-Q2
added 08-10-2022

report update icon

Genmab A/S Balance Sheet 2011-2026 | GMAB

Annual Balance Sheet Genmab A/S

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- -6.94 B -3.37 B -533 M -1.35 B -307 M -874 M -359 M -166 M -61.3 M -53.4 M

Long Term Debt Current

- - 26 M - - - - - - - -

Total Non Current Liabilities

- 769 M 158 M 3.29 M 3.63 M - 1.43 M 178 M 165 M 126 M 101 M

Total Liabilities

- 2.02 B 1.1 B 447 M 331 M 412 M 416 M 834 M 1.07 B 1.31 B 1.08 B

Deferred Revenue

- 26 M - - 151 M 228 M 283 M 550 M 817 M 1.09 B -

Retained Earnings

- 7.11 B 2.13 B -197 M -1.85 B -3.11 B -4.23 B -5.03 B -5.36 B -5.48 B -5.01 B

Total Assets

- 21.1 B 15.1 B 8.46 B 6.6 B 5.24 B 3.9 B 2.87 B 1.73 B 1.69 B 1.56 B

Cash and Cash Equivalents

- - 3.55 B 533 M 1.35 B - - - - - -

Book Value

- 19.1 B 14 B 8.01 B 6.27 B 4.83 B 3.49 B 2.03 B 660 M 383 M 486 M

Total Shareholders Equity

- - 14 B 8.01 B 6.27 B - - - - - -

All numbers in DKK currency

Quarterly Balance Sheet Genmab A/S

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - 554 M - 363 M - 363 M - 277 M - 313 M - 155 M - 163 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - 1.05 B - 863 M - 880 M - 769 M - 803 M - 158 M - 166 M - 3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - 2.99 B - 2.43 B - 2.23 B - 2.02 B - 2.81 B - 1.1 B - 691 M - 447 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - 12.2 B - 10 B - 8.16 B - 7.11 B - 5.88 B - 2.13 B - 32 M - -198 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - 27.5 B - 24.6 B - 22.5 B - 21.1 B - 20.7 B - 15.1 B - 8.98 B - 8.46 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - 9.82 B - 8.96 B - 9.48 B - 7.26 B - 6.6 B - 3.55 B - 583 M - 533 M - 1.09 B - 1.35 B - - - 307 M - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- - 24.5 B - 22.2 B - 20.3 B - 19.1 B - 17.9 B - 14 B - 8.29 B - 8.01 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - 24.5 B - 22.2 B - 20.3 B - 19.1 B - 17.9 B - 14 B - 8.29 B - 8.01 B - 6.86 B - 6.27 B - - - 4.83 B - - - - - - - - - - - - - - - - - - - - - - -

All numbers in DKK currency

Balance Sheet is a fundamental financial report of Genmab A/S, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.21 -0.42 % $ 208 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Altimmune Altimmune
ALT
$ 3.35 -2.62 % $ 295 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 216.26 -0.83 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.12 -0.57 % $ 894 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 0.62 2.14 % $ 7.1 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 46.45 -0.91 % $ 4.18 B schweizSchweiz
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.4 -0.36 % $ 357 M britainBritain
Exelixis Exelixis
EXEL
$ 41.13 -0.69 % $ 11.2 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.63 - $ 16.5 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
$ 6.64 -3.63 % $ 421 K usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 7.64 -0.72 % $ 6.83 B spainSpain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Halozyme Therapeutics Halozyme Therapeutics
HALO
$ 61.68 -1.88 % $ 7.39 B usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 26.99 -2.21 % $ 1.55 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 6.43 0.31 % $ 52.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Immatics N.V. Immatics N.V.
IMTX
$ 9.32 -2.0 % $ 586 M germanyGermany
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
$ 69.48 -1.85 % $ 11.1 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.33 -2.92 % $ 235 M franceFrance
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.29 -2.94 % $ 822 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA